[Skip to Content]
[Skip to Content Landing]
Citations 0
News From the Food and Drug Administration
June 7, 2000

New Therapy for Macular Degeneration

Author Affiliations

Not Available

Not Available

JAMA. 2000;283(21):2779. doi:10.1001/jama.283.21.2779-JFD00004-2-1

The FDA has approved verteporfin for injection (Visudyne, QLT Photo Therapeutics, Vancouver, BC, and CIBA Vision, Duluth, Ga) for the treatment of age-related macular degeneration in patients with predominantly classic subfoveal choroidal neovascularization (CNV). The treatment is a two-stage process requiring administration of verteporfin for injection followed by light at a wavelength of/689±3nm from a nonthermal diode laser. Light activation of verteporfin in the plasma results in local damage to neovascular endothelium and consequent vessel occlusion.